Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MTPC Agrees to Transfer Tanabe Europe Shares to API in Tokyo
April 4, 2013
- Protected Drugs Represent More than 50% of Bayer Yakuhin Sales in 2012, Over 60% Eyed by 2014: Pres. Brunn
April 4, 2013
- Mochida Aims at Sales of 104 Billion Yen in FY2015
April 4, 2013
- Presidents of Pharmaceutical Companies Stress Globalization, Compliance in Welcoming Ceremonies for New Employees
April 4, 2013
- Nihon Chouzai to Make Choseido Subsidiary, to Sell Its Products Through Nihon Generic
April 4, 2013
- Plavix Rises to 3rd Place in Domestic Ethical Drug Market in 2012, Could Take No. 1 Spot This Year
April 4, 2013
- MSD Reports Downturn in Profits for 2012 Despite 2.7% Growth in Sales
April 3, 2013
- AZ K.K. Reports 5.1% Decline in 2012 Sales; Sales of Omepral and Casodex Down
April 3, 2013
- Bayer Yakuhin Reports Nearly 20% Drop in Operating Profit Despite Growth in Sales of Zetia
April 3, 2013
- Abbott Japan Names Mr Sakamoto as President, Mr Honda as Vice President
April 3, 2013
- Janssen Poised to Keep Up Double-Digit Growth, Focus on 5 Therapeutic Areas: Japan Pres. Goodwin
April 3, 2013
- Kaketsuken also Files NDA for Cell Culture-Based New Influenza Vaccine
April 3, 2013
- Taiho Assigns 54 Oncology MRs according to Cancer Type
April 3, 2013
- AZ Takes Over Rights to Byetta and Bydureon; Bydureon Expected to Be Launched in May
April 2, 2013
- DSP Signs Agreement with Edison Pharmaceuticals of US for Mitochondrial Disease Treatments
April 2, 2013
- Gabriel Baertschi Takes Over as President of AZ K.K.
April 2, 2013
- MTPC Obtains Approval of SGLT-2 Inhibitor Canagliflozin in US
April 2, 2013
- 3 Companies’ Midterm Plans Foresee Poor Outlook for Domestic Market with “For-Reference-Only Figures,” “No Figures,” “Zero Growth”
April 2, 2013
- Mr Ninomiya Appointed as New President, Mr Mitani Exits to Become Advisor: Novartis Pharma
April 1, 2013
- Announcement: 6th annual Marketing Excellence Japan 2013 – Hilton Tokyo, May 14 – 15
April 1, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…